Panacea Biotec Limited

Panacea Biotec Limited a biotechnology company engages in the research and development manufacture and marketing of pharmaceutical formulations and vaccines in India. It operates through Vaccines and Formulations segments. The company's product portfolio includes prescription products in various therapeutic areas such as pain management diabetes and cardiovascular management oncology renal disease management osteoporosis management anti-tubercular and gastro-intestinal care; and pneumococcal vaccine dengue tetravalent vaccine typhoid conjugate vaccine and universal flu vaccine. It also exports its products to approximately 30 countries including the United States Germany the Russian Federation Brazil Turkey Bosnia Tanzania Kenya Serbia Vietnam Sri Lanka the Philippines Panama Ecuador Trinidad and Tobago etc. The company has a collaboration agreement with the Russian Direct Investment Fund for producing Covid-19 vaccine Sputnik-V; and the Coalition for Epidemic Preparedness Innovations and Translational Health Science and Technology Institute to develop vaccine candidates that could protect against SARS-Cov-2 variants and other Beta coronaviruses. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi India.